DR not main cause of blindness in diabetics

Article

Diabetic retinopathy (DR) is not the leading cause of ocular co-morbidity in diabetic subjects, according to a study published in the June 2008 issue of the British Journal of Ophthalmology.

Diabetic retinopathy (DR) is not the leading cause of ocular co-morbidity in diabetic subjects, according to a study published in the June 2008 issue of the British Journal of Ophthalmology.

Peter H. Scanlon, MBBS, MD, FRCP, DCH, DRCOG, DO, MRCOphth of Cheltenham General Hospital and colleagues conducted slip-lamp biomicroscopy examinations on diabetic subjects (n=1549) following assessment of best corrected visual acuity (BCVA) by a standardized logarithm of minimum angle resolution (logMAR).

The researchers found subnormal vision (logMAR ≥0.3) in 9.0% of subjects; blindness (logMAR ≥1.3), in 0.45%. For any given eye, sensitivity of subnormal vision was 33.4%, specificity was 85.9%, positive status was 18.6% and negative status was 93.0% predictive of DR. Lenticular opacity, macular degeneration, diabetic maculopathy, other media causes including corneal opacity, and amblyopia were found to be contributory causes of moderate visual loss (logMAR 0.50–0.98) or acuity blindness (logMAR ≥1.0) in 49%, 29%, 15%, 13% and 10% of subjects, respectively.

The researchers concluded that BCVA in isolation is not a reliable indicator of DR, and that DR is not the primary cause of vision loss in diabetic subjects.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.